Boston Scientific Uncapped Contingent Considertation increased by 8.5% to $115.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 17.3%, from $139.00M to $115.00M.
other_uncapped_contingent_considertation| Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|
| Value | $164.00M | $163.00M | $139.00M | $151.00M | $106.00M | $115.00M |
| QoQ Change | — | -0.6% | -14.7% | +8.6% | -29.8% | +8.5% |
| YoY Change | — | — | — | -7.9% | -35.0% | -17.3% |